Protein expression of MDM2 and its clinicopathological relationships in human hepatocellular carcinoma

Liver

Volumn 20, Issue 3, 2000, Pages 209-215

  Endo, Kanenori ^a   Ueda, Tsuyoshi ^a   Ohta, Tetsuo ^b   Terada, Tadashi ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinicopathologic correlation; Hepatocellular carcinoma; Immunohistochemistry; mdm2; Survival

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL NUCLEUS; CORRELATION FUNCTION; FEMALE; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; SURVIVAL RATE;

EID: 0034086242     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2000.020003209.x     Document Type: Article

References (53)

1. MICHALOVITZ D, HALEVY O, OREN M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant p53. Cell 1990; 62: 671-80.
2. LOWE S W, SCHMITT E M, SMITH S W, OSBORNE B A, JACKS T. p53 is required for radiation-induced apotosis in mouse thymocytes. Nature 1993; 362: 847-9.
3. EL-DEIRY W S, TORINO T, VELCULESCU V E. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
4. BARAK Y, JUVEN T, HAFFNER R, OREN M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12: 461-8.
5. CHO Y, GORINA S, JEFFREY P D, PAVLEETICH N P. Crystal structure of a p53 tumour suppressor-DNA complex: understanding tumourigenic mutations. Science 1994; 265: 346-55.
6. OLINER J D, KINZLER K W, MELTZER P S, GEORGE D L, VOGELSTEIN B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-3.
7. MOMAND J, AMBETTI G P, OLSON D C, GEORGE D, LEVINE A J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-15.
8. FAKHARZADEH SS, TRUSKO SP, GEORGE DL. Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 1991; 10: 1565-9.
9. WU X, BAYLE J H, OLSO D, LEVINE A J. The p53-mdm2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-32.
10. KONDO S, MORIMURA T, BARNETT G H, et al. The transforming activities of MDM2 in cultured neonatal rat astrocytes. Oncogene 1996; 13: 1773-9.
11. MOMAND J, ZAMBETTI G P. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 1996; 12: 2279-89.
12. HAUPT Y, MAYA R. KAZAZ A, OREN M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-9.
13. KUBBUTAT M H, JONES S N, VOUSDEN K H. Regulation of p53 stability by Mdm2. Nature 1997; 387: 299-303.
14. HAUPT Y. BARAK Y, OREN M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J 1996; 15: 1596-606.
15. CHEN C Y, OLINER J D, ZHAN Q, FORNACE A J JR, VOGELSTEIN B, KASTAN MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci USA 1994; 91: 2684-8.
16. JONES S N, ROE A E, DONEHOWER L A, BRADLEY A. Rescue of embryonic lethality in Mdm-2 deficient mice by absence of p53. Nature 1995; 378: 206-8.
17. KUBBUTAT M H, LUDWIG R L, ASHCROFT M, VOUSDEN K H. Regulation of mdm2-directed degradation by the C terminus of p53. Mol Cell Biol 1998; 18: 5690-8.
18. OLINER J D, PIETTENPOL J A, THIAGALINDAM S, GYURIS J, KINZLER W K, VOGELSTEIN B. Oncoprotein MDM2 conceals the activation domain of suppressor p53. Nature 1993; 362: 857-60.
19. PERRY M E, LEVINE A J. p53 and mdm-2: interactions between tumor-suppressor gene and oncogene product. Mt Sinai J Med 1994; 61: 291-9.
20. MARTIN K, TROUCHE D, HAGEMELER C, et al. Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein. Nature 1995; 375: 691-4.
21. XIAO Z-X, CHEN J, LEVINE AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995; 375: 694-8.
22. LEACH F S, TORINO T, MELTZER P, et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-4.
23. HABUCHI T, KINOSHITA H, YAMADA H, et al. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. J Natl Cancer Inst 1994; 86: 1331-5.
24. REIFENBERGER G, LIU L, ICHIMURA K, SCHMIDT E E, COLLINS V P. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-9.
25. WABER PG, CHEN J, NISEN P D. Infrequency of MDM2 gene amplification in pediatric solid tumors and lack of association with p53 mutations in adult squamous cell carcinomas. Cancer Res 1993; 53: 6028-30.
26. QUESNEL B, PREUDHOMME C, FOURNEIER J, FENAUX P, PEYRAT J P. MDM2 gene amplification in human breast cancer. Eur J Cancer 1994; 30: 982-4.
27. INADA K, TOI M, YAMAMOTO Y, et al. Immunocytochemical analysis of MDM2 protein expression and its relevance to tumor angiogenesis in primary breast cancer. Oncol Rep. 1996; 3: 667-71.
28. LIANES P, ORLOW I, ZHANG Z F, et al. Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst. 1994; 86: 1325-30.
29. MARCHETTI A, BUTTITTA F, GILANDO S, et al. mdm2 gene alterations and mdm2 protein expression in breast carcinoma. J Pathol 1995; 175: 31-8.
30. BAUNOCH D A, WATKINS L F, TEWARI A, et al. MDM2 overexpression in benign and malignant lesions of the human breast: association with ER expression. Int J Oncol 1996; 8: 895-9.
31. JIANG M, SHAO ZM, WU J, et al. p21/waf1/cip1 and mdm2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 1997; 74: 529-34.
32. SHIMADA Y, IMAMURA M, SHIBAGAKI I, et al. Genetic alterations in patients with esophageal cancer with short- and long- term survival rates after curative esophagectomy. Ann Surg 1997; 226: 162-8.
33. GUDAS J M, NGUYEN H, KLEIN R C, KATAYOSE D, SETH P, COWAN K H. Differential expression of multiple MDM2 messenger RNAs and proteins in normal and tumorigenic breast epithelial cells. Clin Cancer Res 1995; 1: 71-80.
34. SHEIKH M S, SHAO Z M, HUSSAIN A, FONTANA J A. The p53-binding protein MDM2 gene is differentially expressed in human breast carcinoma. Cancer Res 1993; 53, 3226-8.
35. SIGALAS I, CALVERT H, ANDERSON J J, NEAL D E, LUNEC J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med 1996; 2: 912-7.
36. QIU S J, YE S L, WU Z Q, TANG Z Y, LIU Y K. The expression of the mdm2 gene may be related to the aberration of the p53 gene in human hepatocellular carcinoma. J Cancer Res Clin Oncol 1998; 124: 253-8.
37. OHNISHI H, KAWAMURA M, HANADA R, et al. Infrequent mutations of the TP53 gene and no amplification of the MDM2 gene in hepatoblastomas. Genes Chromosomes Cancer 1996; 15: 187-90.
38. MURAKAMI Y, HAYASHI K, HIROHASHI S, SEKIYA T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991; 51: 5520-5.
39. NOSE H, IMAZEKI F, OHIO M, OMATA M. p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer 1993; 72: 355-60.
40. NAKA T, TOYOTA N, KANEKO T, KAIBARA N. Protein expression of p53, p21WAF1, and Rb as prognostic indicators in patients with surgically treated hepatocellular carcinoma. Anticancer Res 1998; 18: 555-64.
41. CASEY G, LOPEZ M E, LAMOS J C, et al. DNA sequence analysis of exon 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996; 13: 1971-81.
42. SHIMADA Y, IMAMURA M, WATANABE G, et al. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999; 80: 1281-8.
43. WURL P, MEYE A, SCHMIDT H, et al. High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities. Oncogene 1998; 16: 1183-5.
44. WURL P, MEYE A, BERGER D, et al. Significance of retinoblastoma and mdm2 gene expression as prognostic makers for soft-tissue sarcoma. Langenbecks Arch Surg 1998; 383: 99-103.
45. LIVER CANCER STUDY GROUP OF JAPAN. The general rules for the clinical and pathological study of primary liver cancer (The 3rd Edition). Tokyo: Kanehara Press; 1992.
46. IGGO R, GATTER K, BARTEK J, LANE D, HARRIS A L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675.
47. SOMMER S S, CUNNINGHAM J, MCGOVERN R M, et al. Pattern of p53 gene mutations in breast cancers of women of the midwestern United States. J Natl Cancer Inst 1992; 84: 246.
48. KOHLER M F, BERCHUCK A, DAVIDOFF A M, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992; 52: 1622.
49. VAHAKANGAS K H, SAMET J M, METCALF R A, et al. Mutations of p53 and ras genes in randon-associated lung cancer from uranium miners. Lancet 1992; 339: 576.
50. TERADA T, SHIMIZU K, IZUNI R, NAKANUMA Y. p53 expression in formalin-fixed, paraffin-embedded archival specimens of intrahepatic cholangiocarcinoma: retrieval of p53 antigenicity by microwave oven heating of tissue sections. Mod Pathol 1994; 7: 249-52.
51. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-23.
52. ZHANG Y, XIONG Y, YARBROUGH W G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-34.
53. JUVEN-GERSHON T, SHIFMAN O, UNGER T, ELKELES A, HAUPT Y, OREN M. The mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol Cell Biol 1998; 18: 3974-82.